PODD
$259.10
Insulet
($3.57)
(1.36%)
PODD
Earnings Whisper ®
N/A
1st Quarter March 2021
Consensus:  $0.05
Revenue:  $245.50 Mil
Tuesday
May 25
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Guidance announcement made Tuesday, February 23, 2021

What do you expect when PODD reports earnings?
Beat
Meet
Miss

Where is PODD's stock price going from here?
Up
Flat
Down
Stock chart of PODD
Analysts
Summary of analysts' recommendations for PODD
Score
Grade
Pivots
Resistance
$278.78
$274.52
$266.81

$262.56

Support
$254.85
$250.59
$242.88
Tweet
Growth
Description
INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes.
Peers
StrykerBoston ScientificBecton, DickinsonBaxter InternationalAbbottWatersIntegra LifeSciences HoldingsCardiovascular Systems3MTeleflex